Last Updated : July 27, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| Venclexta | Venetoclax | Withdrawn | ||||
| Cyramza | Ramucirumab | Cancelled | ||||
| Avastin | Bevacizumab | Withdrawn | ||||
| TBD | Cabozantinib | Withdrawn | ||||
| Erbitux | Cetuximab | Cancelled | ||||
| Atriance | Nelarabine | Cancelled | ||||
| TBD | Entrectinib | Withdrawn | ||||
| Tecentriq | Atezolizumab | Withdrawn | ||||
| Admelog | Insulin lispro | Cancelled |
Last Updated : July 27, 2024